NASDAQ · GRALV
GRAIL, Inc. Common Stock
Healthcare · Medical - Diagnostics & Research
$18.63
Up+$1.41 (+8.19%)
Updated Oct 7, 2026, 2:38 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 579.39M
- P/E ratio
- —
- Dividend yield
- —
- 52-week range
- — – —
- Volume
- 606.4K
- Avg. volume
- 2.41M
Price performance · GRALV
GRALV price history
1M range · 0 trading sessions · Daily adjusted prices
GRALV does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest GRALV news
The latest Smart Investors Daily articles mentioning GRALV.
Stock researchCompany · Overview
Company
Market Activity
Research & News
GRALV research
Overview
Company profile and research snapshot.
Company profile
GRAIL, LLC, a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. GRAIL, LLC was formerly known as PSC15, Inc. and changed its name to GRAIL, LLC in January 2016. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, LLC operates as a subsidiary of Illumina, Inc.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
